Hawaii Biotech is a cutting-edge brand dedicated to targeting infectious diseases and creating a safer world. With a focus on medical countermeasures, they are developing small molecule drug candidates for the treatment of Anthrax intoxication and botulism caused by BoNT type A intoxication. Their recombinant subunit protein vaccine pipeline includes several candidates targeting emerging and re-emerging infectious diseases.

These vaccines are supported by their stable insect cell vaccine platform, ensuring high-quality proteins with a native-like structure. Hawaii Biotech's protein production platform has demonstrated the ability to generate proteins that elicit immune responses equivalent to, or even better than, traditional methods. Additionally, their semi-synthetic saponin adjuvant, GPI-0100, helps stimulate broad immune responses to both vaccines and therapeutics.

With a dedicated team, strong collaborations, and advanced technology, Hawaii Biotech is at the forefront of innovative solutions in the field of infectious disease prevention. Visit their website to learn more about their groundbreaking work